81 related articles for article (PubMed ID: 17651051)
1. Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
Larsen RH; Borrebaek J; Dahle J; Melhus KB; Krogh C; Valan MH; Bruland OS
Cancer Biother Radiopharm; 2007 Jun; 22(3):431-7. PubMed ID: 17651051
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Melhus KB; Larsen RH; Stokke T; Kaalhus O; Selbo PK; Dahle J
Cancer Biother Radiopharm; 2007 Aug; 22(4):469-79. PubMed ID: 17803441
[TBL] [Abstract][Full Text] [Related]
3. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
4. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
Dahle J; Krogh C; Melhus KB; Borrebaek J; Larsen RH; Kvinnsland Y
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):886-95. PubMed ID: 19679402
[TBL] [Abstract][Full Text] [Related]
6. DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.
Bravo MG; Egorova BV; Vasiliev AN; Lapshina EV; Ermolaev SV; Durymanov MO
Curr Radiopharm; 2023 Jun; 16(3):233-242. PubMed ID: 36809934
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.
Dadwal M; Kang CS; Song HA; Sun X; Dai A; Baidoo KE; Brechbiel MW; Chong HS
Bioorg Med Chem Lett; 2011 Dec; 21(24):7513-5. PubMed ID: 22047687
[TBL] [Abstract][Full Text] [Related]
8. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
Lewis MR; Shively JE
Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
[TBL] [Abstract][Full Text] [Related]
9. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
10. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
[TBL] [Abstract][Full Text] [Related]
11. Preparation of
Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
[TBL] [Abstract][Full Text] [Related]
12. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
13. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
17. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging.
Smith-Jones PM; Solit DB
Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256
[No Abstract] [Full Text] [Related]
18. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
19. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.
Moreau M; Raguin O; Vrigneaud JM; Collin B; Bernhard C; Tizon X; Boschetti F; Duchamp O; Brunotte F; Denat F
Bioconjug Chem; 2012 Jun; 23(6):1181-8. PubMed ID: 22519915
[TBL] [Abstract][Full Text] [Related]
20. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
Beckford Vera DR; Eigner S; Eigner Henke K; Leyva Montaña R; Melichar F; Beran M
Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]